The Assessment and Management of Biliary Atresia in Hawai‘i, 2009–2023

• Published in: Hawai'i journal of health & social welfare 2024-10, Vol.83 (10), p.268-273
• Main Authors: Singh, Sneha A., Balaraman, Kalpana K., Johnson, Madeline I., Balaraman, Venkataraman, Puapong, Devin P., Johnson, Sidney M., Tabak, Benjamin D., Woo, Russell K.
• Format: Article
• Language: English
• ISSN: 2641-5216; 2641-5224
• DOI: 10.62547/NUOX8943

Although biliary atresia (BA) is a rare neonatal disorder, it remains the leading cause of pediatric end-stage liver disease. Early diagnosis of BA and treatment with the Kasai procedure can significantly reduce the need for pediatric liver transplant. Current data suggests that performing the Kasai procedure at 30–45 days of life is associated with longer native liver survival rates and reduction of the need for liver transplant. The incidence rate of BA in the state of Hawai‘i is nearly double the incidence rate in the continental US. International studies have demonstrated that screening programs for BA reduce the age at diagnosis and treatment. However, there has been no statewide analysis on the ages at diagnosis or at Kasai, nor does a statewide screening program for BA exist. The purpose of this study is to review the age of diagnosis and treatment of BA to determine if the current practice in Hawai‘i is in line with the published data. A retrospective chart review of all patients diagnosed with BA at the state’s primary children’s hospital was performed (2009–2023) and 19 patients who underwent the Kasai procedure were identified. The mean age at diagnosis is 71.4 days (n=19) and the mean age at Kasai procedure is 72.0 days (n=19). Both the average age at diagnosis and treatment for BA in Hawai‘i is significantly higher than published data suggesting best outcomes at 30–45 days of life. This review suggests that the implementation of a statewide screening program for BA in Hawai‘i is warranted.